



SYNCOM FORMULATIONS (INDIA) LTD.

Regd. Off.: 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E), MUMBAI - 400 093
Works : 256-257, Sector - 1, Pithampur (Dhar), E-mail : info@sfil.in, www.sfil.in, CIN: L24239MH1988PLC047759

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2017

Particulars (Rs. In lacs)	Standalone				Consolidated		
	Quarter Ended		Year Ended		Year Ended		
	31.03.2017 (Audited)*	31.12.2016 (Unaudited)	31.03.2016 (Audited)*	31.03.2017 (Audited)	31.03.2016 (Audited)	31.03.2016 (Audited)	
1 Revenue from Operations	4826.10	4489.69	4731.36	18275.09	18190.48	18275.09	18190.48
2 Other Income	97.41	108.43	156.75	486.24	466.05	486.24	466.05
3 Total Revenue (1+2)	4923.51	4598.12	4888.11	18761.33	18656.53	18761.33	18656.53
4 Expenses							
(a) Cost of Materials consumed	1775.36	1796.62	819.39	6902.10	6890.03	6902.10	6890.03
(b) Purchase of stock in trade	1325.25	1359.81	2955.06	5412.19	6630.17	5412.19	6630.17
(c) Changes in inventories of finished goods, work in progress and stock in trade	228.94	(24.45)	(282.50)	496.71	(365.04)	496.71	(365.04)
(d) Employee benefits expenses	470.08	330.06	375.78	1461.68	1361.37	1461.68	1361.37
(e) Finance cost	7.03	7.48	2.09	28.18	7.09	28.18	7.09
(f) Depreciation and amortization expenses	62.28	80.00	44.81	312.28	299.81	312.28	299.81
(g) Other expenses	742.02	582.89	593.87	2559.54	2212.82	2559.54	2212.82
Total Expenses (4)	4610.96	4132.41	4508.50	17172.68	17036.25	17172.68	17036.25
5 Profit/(Loss) from before exceptional & extraordinary and tax (3-4)	312.55	465.71	379.61	1588.65	1620.28	1588.65	1620.28
6 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
7 Profit/(Loss) before extraordinary items & tax (5-6)	312.55	465.71	379.61	1588.65	1620.28	1588.65	1620.28
8 Extraordinary items	0.90	00.00	10.19	0.90	10.19	0.90	10.19
9 Profit before tax (7-8)	311.65	465.71	369.42	1587.75	1610.09	1587.75	1610.09
10 Tax expenses							
a) Current Tax	28.26	185.00	144.23	403.26	574.53	403.26	574.53
b) Deferred Tax	61.08	0.00	0.00	131.08	0.00	131.08	0.00
11 Profit/(Loss) for the period from continuing operations (9-10)	222.31	280.71	225.19	1053.41	1035.56	1053.41	1035.56
12 Profit/(Loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13 Tax expenses of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
14 Profit/(Loss) from discontinuing operations (after tax) (12-13)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15 Profit/(Loss) for the period (11)	222.31	280.71	225.19	1053.41	1035.56	1053.41	1035.56
16 Earning Per Share (EPS)							
a) Basic	0.03	0.04	0.03	0.13	0.13	0.13	0.13
b) Diluted	0.03	0.04	0.03	0.13	0.13	0.13	0.13

STATEMENT OF SEGMENT-WISE REVENUE, RESULTS AND CAPITAL EMPLOYED

Particulars (Rs. In lacs)	Standalone				Consolidated		
	Quarter Ended		Year Ended		Year Ended		
	31.03.2017 (Audited)*	31.12.2016 (Unaudited)	31.03.2016 (Audited)*	31.03.2017 (Audited)	31.03.2017 (Audited)	31.03.2016 (Audited)	
1 Segment Revenue							
(a) Pharmaceuticals Drugs & Formulations	3767.63	3750.84	4822.43	15423.76	16862.49	15423.76	16862.49
(b) Trading of Commodities	1129.92	804.76	40.25	3127.10	1713.43	3127.10	1713.43
(c) Renting of Property	25.96	42.52	25.43	210.46	80.61	210.46	80.61
Total	4923.51	4598.12	4888.11	18761.32	18656.53	18761.32	18656.53
Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales/Income from Operations	4923.51	4598.12	4888.11	18761.32	18656.53	18761.32	18656.53
2 Segment Results (Profit)+/Loss(-) before tax and interest from each Segment							
(a) Pharmaceuticals Drugs & Formulations	291.31	320.10	349.22	1162.89	1463.91	1162.89	1463.91
(b) Trading of Commodities	2.30	110.57	7.04	243.47	82.84	243.47	82.84
(c) Renting of Property	25.96	42.52	25.43	210.46	80.61	210.46	80.61
Total	319.57	473.19	381.69	1616.82	1627.36	1616.82	1627.36
Less: (i) Interest	7.03	7.48	2.09	28.18	7.09	28.18	7.09
(ii) Other Un-allocable Expenditure (net off Un-allocable Income)	0.90	0.00	10.19	0.90	10.19	0.90	10.19
Total Profit Before Tax	311.64	465.71	369.42	1587.74	1610.09	1587.74	1610.09
3 Segment Assets							
(a) Pharmaceuticals Drugs & Formulations	13833.43	13053.41	14111.73	13833.43	14111.73	13834.00	14111.73
(b) Trading of Commodities	314.44	514.72	94.49	314.44	94.49	314.44	94.49
(c) Renting of Property	3868.81	3815.69	3333.95	3868.81	3333.95	3868.81	3333.95
(d) Unallocated	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Assets	18016.68	17383.83	17540.17	18016.68	17540.17	18017.25	17540.62
4 Segment Liabilities							
(a) Pharmaceuticals Drugs & Formulations	6064.02	5078.57	6597.27	6064.02	6597.27	6064.59	6597.27
(b) Trading of Commodities	160.56	413.06	31.81	160.56	31.81	160.56	31.81
(c) Renting of Property	56.64	191.13	41.13	56.64	41.13	56.64	41.13
(d) Unallocated	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	6281.22	5692.76	6670.21	6281.22	6670.21	6281.79	6670.66





SYNCOM FORMULATIONS (INDIA) LTD.

Regd. Off.: 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E), MUMBAI - 400 093
 Works : 256-257, Sector - 1, Pithampur (Dhar), E-mail : info@sfil.in, www.sfil.in, CIN: L24239MH1988PLC047759

STATEMENT OF ASSETS & LIABILITY AS AT 31/03/2017

Particulars (Rs. in lacs)	Standalone		Consolidated	
	As at 31/03/2017 Audited	As at 31/03/2016 Audited	As at 31/03/2017 Audited	As at 31/03/2016 Audited
A. EQUITY AND LIABILITIES				
Shares holders' fund				
(a) Share capital	7806.52	7806.52	7806.52	7806.52
(b) Reserve and surplus	3928.94	3063.44	3928.94	3063.44
(c) Money received against share warrants	0.00	0.00	0.00	0.00
Sub total - shareholders' funds	11735.46	10869.96	11735.46	10869.96
Share application money pending allotment	0.00	0.00	0.00	0.00
Minority interest	0.00	0.00	0.00	0.00
Non-current liabilities				
(a) Long-term borrowing	0.00	0.00	0.00	0.00
(b) Deferred tax liabilities (net)	715.65	584.57	715.65	584.57
(c) Long-term liabilities	57.64	42.13	57.64	42.13
(d) Long-term provisions	0.00	0.00	0.00	0.00
Sub total - noncurrent liabilities	773.29	626.70	773.29	626.70
Current liabilities				
(a) Short-term borrowing	1245.14	562.20	1245.14	562.20
(b) Trade payables	3226.14	4693.62	3226.71	4694.07
(c) Other current liabilities	584.31	366.79	584.31	366.79
(d) Short-term provisions	452.34	420.90	452.34	420.90
Sub total - current liabilities	5507.93	6043.51	5508.50	6043.96
TOTAL - EQUITY AND LIABILITIES	18016.68	17540.17	18017.25	17540.62
B. ASSETS				
Non-current assets				
(a) Fixed assets	5528.75	5056.86	5528.75	5056.86
(b) Goodwill on consolidation	0.00	0.00	0.00	0.00
(c) Non-current investments	3601.97	2347.43	3591.30	2336.75
(d) Deferred tax assets (net)	0.00	0.00	0.00	0.00
(e) Long-term loans and advances	618.43	1505.42	618.43	1505.42
(f) Other non-current assets	0.00	0.00	0.00	0.00
Sub total - noncurrent assets	9749.15	8909.71	9738.48	8899.03
Current assets				
(a) Current investments	0.00	0.00	0.00	0.00
(b) Inventories	1000.93	1546.81	1000.93	1546.81
(c) Trade receivables	4599.46	4599.69	4599.46	4599.69
(d) Cash and cash equivalents	651.95	569.41	651.95	569.41
(e) Short-term loans and advances	1924.52	1869.87	1924.52	1869.87
(f) Other current assets	90.67	44.68	101.91	55.81
Sub total - current assets	8267.53	8630.46	8278.77	8641.59
TOTAL ASSETS	18016.68	17540.17	18017.25	17540.62

Notes :

- The above Standalone and Consolidated Audited Financial Results were approved by the Audit Committee and Board of Directors at their meetings held on 30th May 2017.
- The company is operating in three segment i.e.: (a) Pharmaceutical Drugs & Formulations. (b) Trading of commodities and (c) Renting of Property, particulars for segment wise results enclosed herewith.
- The Board has recommended a dividend @ Re. 0.02 per share of Re. 1/- each (2%) subject to approval of the member in the forthcoming AGM.
- Figures have been regrouped/reclassified wherever necessary.
- *The figures of last quarter are the balancing figures between audited figures in respect of the full financial year & the published year to date figures upto the 3rd quarter of that financial year .
- The company is having one wholly owned foreign subsidiary however the said subsidiary has not done any business during the year. Further the same subsidiary has been closed w.e.f. 25th April 2017 and disclosure of closure has been given to stock exchange.
- This statement is as per Regulation 33 of SEBI (LODR) Regulation 2015 and schedule III of the companies act 2013.
- Pursuant to the Second Provision to the Regulation 33(3)(d) of the S EBI (LODR) Regulation 2015, as notified by SEBI on 25th May, 2016 the Board of directors of the Company do hereby declare and confirm that the Auditors Report is unmodified and the Company is not required to submit the Statement of Impact of the Audit Qualifications.

By order of The Board of Directors
For Syncom Formulations (India) Ltd.

Kedarnal Bhandari
Chairman & Whole time Director

Place : Indore
Dated : 30/05/2017